

SUMMARY

Choose **PCRABR** (Flu/RSV) for outpatients.

Do not order PCRABR on inpatients.

USE **RVPCR** (full respiratory panel) for inpatients or immune-compromised and other at risk outpatients.

Please refer to the peak season algorithm on page 2.

If you have any questions about respiratory pathogen testing, please contact Microbiology Technical Specialists, Lisa Scicchitano, B.S., MT(ASCP) at 570-214-4294, Francis Tomaszefski, B.S., MT(ASCP) at 570-271-6185, or Doctoral Directors, Dr. Donna Wolk, MHA, Ph.D, D(ABMM), System Director, Clinical Microbiology at 570-271-7467 or Dr. Raquel Martinez, Ph.D, Director, Clinical Microbiology at 570-271-6338.

For newsletter questions, contact Christy Attinger at (570) 271-6338.

A Publication of Geisinger Medical Laboratories, Microbiology 2014: Vol. (16):1-3, October 31, 2014

10X Essentials:

Respiratory Pathogens Detected by PCR

Effective November 1, 2014, the GMC Microbiology laboratory will offer/perform the following testing scheme for respiratory pathogen detection by Polymerase Chain Reaction (PCR):



Test code PCRABR (FLU A/B and RSV PCR), recommended for outpatients

PCRABR is available November 1 – April 30

Performed only at GMC laboratory

Includes rapid antigen testing for RSV on patients <6 yrs (November 1 – April 30).

NOTE: GBH does not perform rapid RSV testing.

If the rapid RSV results are positive, no further testing is routinely performed.

If the rapid RSV results are negative, PCR testing for influenza A, influenza B and RSV is performed.

Test code RVPCR (Respiratory PCR), for inpatients and the immunocompromised

RVPCR is available year round

Performed at GMC, GBH, GCMC and GWV laboratories

Includes rapid antigen testing for RSV on patients <6 yrs (November 1 – April 30).

NOTE: GBH does not perform rapid RSV testing.


If the rapid RSV results are positive on an outpatient, no further testing is routinely performed.

If the rapid RSV results are positive on an inpatient or negative for all patients, PCR testing for the following respiratory pathogens is performed: adenovirus, coronaviruses: 229E, HKU1, NL63, and OC43, rhinovirus, human metapneumovirus, influenza A (subtypes H1, 2009 H1, and H3), influenza B, parainfluenza virus types 1-4, RSV, Bordetella pertussis, Chlamydomphila pneumoniae, and Mycoplasma pneumoniae.

NOTE: Do not order RVPCR and PCRABR on the same specimen.

See Respiratory Testing Algorithm on next page.

2014-2015 Approved Respiratory Pathogen Testing Algorithm
Geisinger Medical Laboratories, Danville, PA



TEST = RVPCR

Molecular testing full panel: adenovirus; coronaviruses 229E, HKU1, NL63, and OC43; rhinovirus; human metapneumovirus; influenza A (subtypes H1, 2009 H1, and H3); influenza B; parainfluenza virus types 1-4; RSV; *Bordetella pertussis*; *Chlamydomphila pneumoniae*; and *Mycoplasma pneumonia* (at GMC, GWV, coming soon to GCMC; GBH and GSACH sent to GMC)

TEST = PCRABR

Molecular testing abbreviated panel: influenza A influenza B, RSV (performed at GMC for all sites)

Abbreviations

URI = upper respiratory infection
 LRI = lower respiratory tract infection
 UTM = universal transport media w/ flocced swab
 NP = nasopharyngeal
 BAL= brochoalveolar lavage
 RSV = respiratory syncytial virus
 ED = Emergency Department

For questions about respiratory pathogen testing, please contact Microbiology Technical Specialists: Lisa Scicchitano, B.S., MT(ASCP) at 570-214-4294, or Francis Tomashefski, B.S., MT(ASCP) at 570-271-6185 of **Doctoral directors:** Dr. Donna Wolk, MHA, Ph.D, D(ABMM) at 570-271-7467 or Dr. Raquel Martinez, Ph.D, D(ABMM) at 570-271-6338.


*Note: Exceptions to algorithm can occur with laboratory waiver, e.g., patients in high risk groups
 *May 1- Oct 31: rare chance of detecting influenza/ RSV; for diagnostic purposes, the full molecular panel is standard.
 Resp Flow diag Nov thru Apr.vsd

dmwolk, rmmartinez: 12/30/2013, rev 2/5/14,
 rev 10/15/14

Weekly GML RespVIEW: CDC Week 43, 2013-2014

**GML RespVIEW
2013-2014**

Respiratory Viruses



| CDC Respiratory Week, 2013-2014 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 |
|----------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| adenovirus | 0 | 1 | 0 | 0 | 2 | 1 | 3 | 3 | 6 | 5 | 3 | 10 |
| coronavirus | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 2 | 1 | 1 | 3 |
| hum. metapneumovirus | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| influenza A | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 4 | 0 | 0 | 0 |
| influenza B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| parainfluenza | 4 | 3 | 1 | 3 | 4 | 6 | 9 | 12 | 12 | 18 | 24 | 22 |
| respiratory syncytial virus | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| rhinovirus | 10 | 15 | 18 | 10 | 33 | 68 | 84 | 87 | 70 | 82 | 82 | 68 |
| ◆ % Positive Rollup (right axis) | 15% | 18% | 26% | 12% | 30% | 40% | 43% | 45% | 36% | 37% | 40% | 39% |